
|Articles|October 1, 2002
Verteporfin trial tests more frequent doses
Vancouver, Canada-QLT and Novartis are running a new phase IIIB trial of verteporfin (Visudyne) to determine whether better outcomes occur if CNV leakage is treated with a more aggressive treatment regimen in the first 6 months.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
2
New optoretinography technique allows direct measurement of rod function in vivo
3
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
4
Long-lived Greenland sharks may point to new approaches for retinal disease
5












































